Drugs / YH22162
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02496910 | Jun → Sep 2015 | hypertensive disorder | Yuhan Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YH22162 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496910 ↗ |
| Route | Oral | “All subjects will receive a single oral dose of YH22162 FDC or twynsta and Hygroton co-administered in the morning on Day 1.” NCT02496910 ↗ |